Last reviewed · How we verify
Placebo for Glipizide
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trial for Glipizide efficacy in type 2 diabetes.
At a glance
| Generic name | Placebo for Glipizide |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. In this Phase 3 trial, the placebo serves as the comparator arm against Glipizide (an active sulfonylurea) to evaluate the drug's true therapeutic benefit in managing blood glucose levels. Any observed effects in the placebo group are attributed to the placebo effect or natural disease progression.
Approved indications
- Control arm in Phase 3 clinical trial for Glipizide efficacy in type 2 diabetes
Common side effects
Key clinical trials
- A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) (PHASE3)
- Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128) (PHASE3)
- Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1) (PHASE3)
- Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) (PHASE3)
- Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED) (PHASE3)
- Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics (PHASE3)
- To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |